Stimulation of basal and L-DOPA-induced motor activity by glutamate antagonists in animal models of Parkinson's disease

Neuroscience and Biobehavioral Reviews

Volumn 21, Issue 4, 1997, Pages 437-446

  Starr, Michael S ^a   Starr, Beryl S ^b   Kaur, Simranjt ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

AMPA; Glutamate antagonists; NMDA

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; 2 AMINO 5 PHOSPHONOVALERIC ACID; 3 AMINO 1 HYDROXY 2 PYRROLIDINONE; 4 PHOSPHONOMETHYLPIPECOLIC ACID; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; AMANTADINE; AMPA RECEPTOR ANTAGONIST; DEXTROMETHORPHAN; DIZOCILPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; GLUTAMATE RECEPTOR ANTAGONIST; KETAMINE; LAMOTRIGINE; LEVODOPA; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NOMELIDINE; PHENCYCLIDINE; RILUZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; CORPUS STRIATUM; ENTOPEDUNCULAR NUCLEUS; FACILITATION; GLOBUS PALLIDUS; LOCOMOTION; NEUROTRANSMISSION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS;

ANIMALS; ANTIPARKINSON AGENTS; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; LEVODOPA; MOTOR ACTIVITY; PARKINSON DISEASE, SECONDARY; RATS; STIMULATION, CHEMICAL;

EID: 0030984765     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7634(96)00039-5     Document Type: Article

References (69)

1. 1. Albin, R. L.; Makowiec, R. L.; Hollingsworth, Z. R.; Dure, L. S.; Penney, J. B.; Young, A. B., Excitatory amino acid binding sites in the basal ganglia of the rat: A quantitative autoradiographic study. Neuroscience, 46: 35-48 1992.
2. 2. Benazzouz, A.; Boraud, T.; Dubétat, P.; Boireau, A.; Stutzmann, J.-M.; Gross Riluzole, C., Prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. Eur. J. Pharmacol., 284: 299-307 1995.
3. 2 agonists in rats with 6-hydroxydopamine-induced lesions. J. Pharmacol. Exp. Ther., 267: 1454-1459 1993.
4. 4. Bonuccelli, U.; Del Potto, P.; Piccini, P.; Behgé, F.; Corsini, G. U.; Muratorio, A., Dextromethorphan and parkinsonism. Lancet, 340: 53 1992.
5. 5. Brooks, S.; Kaur, S.; Starr, B.S.; Starr, M.S., Myorelaxation with glutamate antagonists in mice correlates with inhibition of rearing and grooming. Pharmacol. Commun., 7: 357-365 1996.
6. 6. Brotchie, J. M.; Mitchell, I. J.; Sambrook, M. A.; Crossman, A. R., Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Mov. Disord., 6: 133-138 1991.
7. 7. Carlsson, M. L., Are the disparate pharmacological profiles of competitive and uncompetitive NMDA antagonists due to different baseline activities of distinct glutamatergic pathways? J. Neural Transm., [Gen. Sect.] 75: 221-226 1993.
8. 8. Carlsson, M.; Carlsson, A., The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J. Neural Transm., 75: 221-226 1989.
9. 9. Carlsson, M.; Carlsson, A., Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice. J. Neural Transm., 77: 65-71 1989.
10. 10. Carlsson, M.; Carlsson, A., Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci., 13: 272-276 1990.
11. 11. Carlsson, M.; Svensson, A., Interfering with glutamatergic neurotransmission by means of NMDA antagonist administration discloses the locomotor stimulatory potential of other transmitter systems. Pharmacol. Biochem. Behav., 36: 45-50 1990.
12. 12. Carlsson, M.; Svensson, A., The non-competitive NMDA antagonists MK-801 and PCP, as well as the competitive NMDA antagonist SDZ EAA494 (D-CPPene), interact synergistically with clonidine to promote locomotion in monoamine-depleted mice. Life Sci., 47: 1729-1736 1990.
13. 13. Carlsson, M.; Svensson, A.; Carlsson, A., Synergistic interactions between muscarinic antagonists, adrenergic agonists and NMDA antagonists with respect to locomotor stimulatory effects in monoamine-depleted mice. Naunyn Schmiedeberg's Arch. Pharmacol., 343: 568-573, 1991.
14. 14. Carroll, C. B.; Holloway, B.; Brotchie, J. M.; Mitchell, I. J., Neurochemical and behavioural mvestigations of the NMDA receptor-associated glycine site in the rat striatum: functional implications for treatment of parkinsonian symptoms. Psychopharmacology, 119: 55-65 1995.
15. 15. Clineschmidt, B. V.; Martin, G. E.; Bunting, P. R.; Papp, N. L., Central sympathomimetic activity of ( + )-5-methyl-10, 11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev. Res., 2: 135-145 1982.
16. 16. Close, S. P.; Elliott, P. J.; Hayes, A. G.; Marriott, A. S., Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease. Psychopharmacology, 102: 295-300, 1990.
17. 17. Criswell, H. E.; Johnson, K. B.; Mueller, R. A.; Breese, G. R., Evidence for involvement of brain dopamine and other mechanisms in the behavioural action of the N-methyl-D-aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats. J. Pharmacol. Exp. Ther., 265: 1001-1010, 1993.
18. 18. Crossman, A. R.; Peggs, D.; Boyce, S.; Luquin, M. R.; Sambrook, M. A., Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey. Neuropharmacology, 28: 1271-1273 1989.
19. 19. Danysz, W.; Gossel, M.; Zajaczkowski, W.; Dill, D.; Quack, G., Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats? Case of amantadine and memantine. J. Neural Transm., [P.D. Sect.] 7: 155-166 1994.
20. 2 agonist interactions in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced hemiparkinsonian monkeys. J. Pharmacol. Exp. Ther., 264: 221-225 1993.
21. 21. Engber, T. M.; Anderson, J. J.; Boldry, R. C.; Papa, S. M.; Kuo, S.; Chase, T. N., Excitatory amino acid receptor antagonists modify regional cerebral metabolic responses to levodopa in 6-hydroxydopamine-lesioned rats. Neuroscience, 59: 389-399 1994.
22. 2 receptors. Eur. J. Pharmacol., 255: 203-213, 1994.
23. 23. Fredriksson, A.; Gentsch, C.; Archer, T., Synergistic interactions between NMDA-antagonists and L-Dopa on activity in MPTP-treated mice. J. Neural Transm., [Gen. Sect.] 97: 197-209 1994.
24. 24. Gancher, S.; Mayer, A., Sensitization to apomorphine-induced rotational behavior in 6-OHDA-lesioned rats: effects of NMDA antagonists on drug response. Brain Res., 682: 63-68 1995.
25. 25. Ginski, M. J.; Witkin, J. M., Sensitive and rapid behavioral differentiation of N-methyl-D-aspartate receptor antagonists. Psychopharmacology, 114: 573-582 1994.
26. 2 agonists in the reserpine-treated mouse are affected differentially by the NMDA receptor antagonist MK 801. J. Neural Transm., [P.D. Sect.] 4: 15-26 1992.
27. 27. Gossel, M.; Schmidt, W. J.; Löscher, W.; Zajaczkowski, W.; Danysz, W., Effect of coadministration of glutamate receptor antagonists and dopaminergic agonists on locomotion in monoamine-depleted rats. J. Neural Transm., [P.D. Sect.] 10: 27-39 1995.
28. 28. Greenamyre, J. T.; O'Brien, C. F., N-Methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch. Neurol., 48: 977-981 1991.
29. 29. Kannari, K.; Markstein, R., Dopamine agonists potentiate antiakinetic effects of competitive NMDA-antagonists in monoamine-depleted mice. J. Neural Transm., [Gen. Sect.] 84: 211-220 1991.
30. 30. Kaur, S.; Starr, M. S., Antiparkinsonian action of dextromethorphan in the reserpine-treated mouse. Eur. J. Pharmacol., 280: 159-166 1995.
31. 31. Kaur, S.; Starr, M. S., Unpublished observations.
32. 32. Kaur, S.; Starr, M. S., Differential effects of intrastriatal and intranigral injections of glutamate antagonists on motor behaviour in the reserpine-treated rat. Neuroscience, 76: 345-354 1997.
33. 1 receptor mechanisms in the potentiation of motor responses to L-DOPA and apomorphine by MK 801 in the reserpine-treated mouse. J. Neural Transm., [P.D. Sect.] 8: 107-116 1994.
34. 34. Klockgether, T.; Turski, L., NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats. Ann. Neurol., 28: 539-546 1990.
35. 35. Klockgether, T.; Turski, L.; Honoré, T.; Zhang, Z.; Gash, D. M.; Kurlan, R.; Greenamyre, J. T., The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine depleted rats and MPTP treated monkeys. Ann. Neurol., 30: 717-723 1991.
36. 36. Klockgether, T.; Turski, L.; Löschmann, P. A.; Wachtel, H., N-Methyl-D-aspartate antagonists stimulate locomotor activity in monoamine depleted rats: Implications for the therapy of Parkinson's disease. In: Lubec, G. Rosenthal, G. A., eds. Amino Acids: Chemistry, Biology and Medicine. Leiden: ESCOM 269-275 1990.
37. 37. Lipton, S. A., Prospects for clinically tolerated NMDA antagonists: Open-channel blockers and alternative redox states of nitric oxide. Trends Neurosci., 16: 527-532 1993.
38. 38. Löscher, W.; Richter, A., The glycine/NMDA receptor ligand (+)-HA-966 but not D-cycloserine has potent antidystonic efficacy in a genetic animal model of dystonia. Eur. J. Pharmacol., 239: 245-247 1993.
39. 39. Löschmann, P. A.; Eblen, F.; Wüllner, U.; Wachtel, H.; Klockgether, T., Lamotrigine has no antiparkinsonian activity in rat models of Parkinson's disease. Eur. J. Pharmacol., 284: 129-134 1995.
40. 40. Löschmann, P. A.; Lange, K. M.; Kunow, M.; Rettig, K. G.; Jähnig, P.; Honoré, T.; Turski, T.; Wachtel, H.; Jenner, P.; Marsden, C. D., Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-Dopa in models of Parkinson's disease. J. Neural Transm., [P.D. Sect.] 3: 203-213 1992.
41. 41. Luquin, M. R.; Obeso, J. A.; Laguna, J.; Guillén, J.; Martinez-Lage, J. M., The AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys. Eur. J. Pharmacol., 235: 297-300 1993.
42. 42. Maj, J.; Rogoz, Z.; Skuza, G., Central effects of CGP 37849 and CGP 39551, competitive NMDA receptor antagonists, in mice. Pol. J. Pharmacol., 45: 349-360 1993.
43. 43. Maj, J.; Skuza, G.; Rogoz, Z., Some central effects of CGP 37849 and CGP 39551, the competitive NMDA receptor antagonists: potential antiparkinsonian activity. J. Neural Transm., [P.D. Sect.] 6: 53-62 1993.
44. 44. Mitchell, I. J.; Hughes, N.; Carroll, C. B.; Brotchie, J. M., Reversal of parkinsonian symptoms by intrastriatal and systemic manipulations of excitatory amino acid and dopamine transmission in the bilateral 6-OHDA lesioned marmoset. Behav. Pharmacol., 6: 492-507 1995.
45. 2 responses in the 6-hydroxydopamine model of Parkinson's disease. Eur. J. Pharmacol., 182: 611-612 1990.
46. 2-mediated behaviour in the 6-hydroxydopamine model of turning: Relationship with c-fos expression. J. Pharmacol. Exp. Ther., 290: 402-408 1992.
47. 47. Ossowska, K., The role of excitatory amino acids in experimental models of Parkinson's disease. J. Neural Transm., [P.D. Sect.] 8: 39-71 1994.
48. 48. Ossowska, K.; Lorenc-Koci, E.; Wolfarth, S., Antiparkinsonian action of MK-801 on the reserpine-induced rigidity: a mechanomyographic analysis. J. Neural Transm., [P.D. Sect.] 7: 143-152 1994.
49. 2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopaminenlepleted striatum in a rat model of Parkinson's disease. J. Neurosci., 12: 3729-3742, 1992.
50. 50. Pierce, R. C.; Rebec, G. V., Intraneostriatal administration of glutamate antagonists increases behavioral activation and decreases neostriatal ascorbate via non-dopaminergic mechanisms. J. Neurosci., 13: 4272-4280 1993.
51. 51. Saenz, R.; Tanner, C. M.; Albers, G.; Kurth, G.; Tetrud, J., A preliminary study of dextromethorphan as adjunctive therapy in Parkinson's disease. Neurology, 43: A115, 15P 1993.
52. 52. Schmidt, W. J.; Bubser, M.; Hauber, W., Behavioural pharmacology of glutamate in the basal ganglia. J. Neural Transm., [Suppl.] 38: 65-89 1992.
53. 53. Skuza, G.; Rogoz, Z.; Quack, G.; Danysz, W., Memantine, amantadine, and L-deprenyl potentiate the action of L-DOPA in monoamine-depleted rats. J. Neural Transm., [Gen. Sect.] 98: 57-67 1994.
54. 54. Slusher, B. S.; Rissolo, K. C.; Jackson, P. F.; Pullan, L. M., Centrally-administered glycine antagonists increase locomotion in monoamine-depleted mice. J. Neural Transm., [Gen. Sect.] 97: 175-185 1994.
55. 2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse, 19: 264-293 1995.
56. 56. Starr, M. S., Antiparkinsonian actions of glutamate antagonists - alone and with L-DOPA: a review of evidence and suggestions for possible mechanisms. J. Neural Transm., [P.D. Sect.] 10: 141-185 1995.
57. 2 receptor-dependent locomotion by glutamate antagonists in the reserpine-treated mouse. Eur. J. Pharmacol., 250: 239-246 1993.
58. 2 agonist apomorphine. J. Neural Transm., [P.D. Sect.] 6: 215-226 1993.
59. 2 dopamine agonists in reserpine-treated mice. Psychopharmacology, 114: 469-476 1994.
60. 60. Starr, M. S.; Starr, B. S., Locomotor effects of amantadine in the mouse are not those of a typical glutamate antagonist. J. Neural Transm., [P.D. Sect.] 9: 31-43 1995.
61. 61. St. Pierre, J.-A.; Bédard, P. J., Intranigral but not intrastriatal micro-injection of the NMDA antagonist MK-801 induced contralateral circling in the 6-OHDA rat model. Brain Res., 660: 255-260, 1994.
62. 62. Svensson, A.; Carlsson, M. L., Injection of the competitive NMDA receptor antagonist AP-5 into the nucleus accumbens of monoamine-depleted mice induced pronounced locomotor stimulation. Neuropharmacology, 31: 513-518 1992.
63. 63. Svensson, A.; Carlsson, M. L.; Carlsson, A., Interaction between glutamatergic and dopaminergic tone in the nucleus accumbens of mice: evidence for a dual glutamateric function with respect to psychomotor control. J. Neural Transm., [Gen. Sect.] 88: 235-240 1992.
64. 2 receptor agonists and the NMDA antagonist dizocilpine in monoamine-depleted mice. J. Neural Transm., [Gen. Sect.] 90: 199-217 1992.
65. 65. Svensson, A.; Pileblad, E.; Carlsson, M., A comparison between the non-competitive NMDA antagonist dizocilpine (MK-801) and the competitive NMDA antagonist DCPPene with regard to dopamine turnover and locomotor-stimulatory properties in mice. J. Neural Transm., [Gen. Sect.] 85: 117-129 1991.
66. 66. Verma, A.; Kulkarni, S. K., Modulation of MK-801 response by dopaminergic agents in mice. Psychopharmacology, 107: 431-436 1992.
67. 67. Wachtel., H.; Kunow, M.; Löschmann, P.A., NBQX (6-nitro-sulfamoyl-benzo-quinoxaline dione) and CPP (3-carboxy-piperazin-propyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats. Neurosci. Lett., 142: 179-182 1992.
68. 68. Wüllner, U.; Kupsch, A.; Arnold, G.; Renner, P.; Scheid, C.; Scheid, R.; Oertel, W.; Klockgether, T., The competitive NMDA antagonist CGP 40116 enhances L-DOPA response in MPTP-treated marmosets. Neuropharmacology, 31: 713-715 1992.
69. 69. Zipp, F.; Baas, H.; Fischer, P.-A., Lamotrigine - antiparkinsonian activity by blockade of glutamate release? J. Neural Transm., [P.D. Sect.] 5: 67-75 1993.